Icon Group operates the largest private cancer clinical trials program in Australia and now expanding into Singapore, Hong Kong and New Zealand.
- 75 TransCelerate-accredited GCP trained investigators
- 25 years of experience delivering clinical trials in the oncology sector
- Within the private healthcare setting, Icon has an unparalleled track record participating in national and international clinical trials, including Phase I to IV
- Icon Research has seen significant growth in 2020 through the recent acquisition and union with the Adelaide Cancer Center for Research (ACCR)
- 18% of studies undertaken at Icon and ACCR are Phase 1 clinical trials
- 33% of participant accrual in 2020 at Icon and ACCR was to Phase 1 clinical trials